Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Cerebrolysin vs Semax
An educational, source-based comparison of Cerebrolysin and Semax — how each peptide works, what it's researched for, and what to know before going deeper.
Porcine-derived peptide mixture researched in neurologic recovery.
A mixture of low-molecular-weight peptides and amino acids derived from purified porcine brain tissue. Research suggests neurotrophic-like activity mimicking BDNF, NGF, and GDNF signaling.
- Ischemic stroke recovery
- Traumatic brain injury
- Vascular dementia and Alzheimer's adjunct
- • Approved in many countries; not FDA-approved in the US.
- • Mixture composition is not fully characterized.
A synthetic heptapeptide derived from ACTH(4-10). Research suggests it modulates BDNF and NGF expression, dopaminergic and serotonergic tone, and shows neuroprotective effects in ischemia models.
- BDNF/NGF upregulation
- Ischemic stroke recovery (clinical use in Russia)
- Attention and cognitive performance
- Anxiolytic-style effects
- • Approved as a medication in Russia; not FDA-approved in the US.
- • Most clinical literature is in Russian.
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
Early-stage research; conclusions are tentative.
Two cited studies; independent replication needed.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| Cerebrolysin | Cerebrolysin in acute ischemic stroke (CARS trial) | Stroke | 2016 | Improved early motor recovery in combination with rehabilitation. |
| Semax | Semax in the treatment of ischemic stroke | Zhurnal Nevrologii i Psikhiatrii | 2018 | Reported improved neurological recovery scores in acute ischemic stroke. |
| Semax | Semax and its analogs in neuroprotection | Molecular Neurobiology | 2020 | Review of neurotrophic and antioxidant mechanisms. |
Side-effect & safety grid
- Approved in many countries; not FDA-approved in the US.
- Mixture composition is not fully characterized.
- Approved as a medication in Russia; not FDA-approved in the US.
- Most clinical literature is in Russian.
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
Cerebrolysin vs Semax — Key differences
- Class: Cerebrolysin is classified as Neurotrophic · Mixture, while Semax is Nootropic · Neuroprotection.
- Primary research focus: Cerebrolysin — ischemic stroke recovery; Semax — bdnf/ngf upregulation.
- Tag: Cognition · Neuroprotection vs Cognition.